osteitis deformans

(redirected from Paget's disease of bone)
Also found in: Thesaurus, Medical, Wikipedia.
Related to Paget's disease of bone: Bone Cancer

osteitis deformans

(dɪˈfɔːmənz)
n
(Pathology) another name for Paget's disease1
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.osteitis deformans - a disease of bone occurring in the middle aged and elderly; excessive bone destruction sometimes leading to bone pain and fractures and skeletal deformities
osteitis - inflammation of a bone as a consequence of infection or trauma or degeneration
References in periodicals archive ?
Comment: In the studies, 347 men and women with moderate to severe Paget's disease of bone received either a single infusion of Reclast or 30 mg of Actonel (risedronate) daily for 60 days.
Unfortunately, there are some glaring deficiencies: raloxifene (Evista), for instance, is not mentioned; risedronate (Actonel) is listed as being approved only for Paget's disease of bone (and not osteoporosis, not even corticosteroid-induced osteoporosis); and the weekly dose of alendronate (Fosamax) is not mentioned.
Evidence for both respiratory syncytial virus and measles virus antigens in the osteoclasts of patients with Paget's disease of bone.
Influence of disodium etidronate on clinical and laboratory manifestations of Paget's disease of bone (osteitis deformans).
The report is an essential source of information and analysis on the global Paget's disease of Bone market.
Before patients take FORTEO, patients should tell their healthcare provider if they have Paget's disease of bone, are a child or young adult whose bones are still growing or have had radiation therapy.
Paget's disease of bone can be focal or multifocal and affects both men and women.
Paget's disease of bone is a chronic, focal skeletal disorder characterized by greatly increased and disorderly bone remodeling.
Lyles said at a meeting sponsored by the Paget Foundation for Paget's Disease of Bone and Related Disorders.
Duration of the effects of oral diphosphonate therapy in Paget's disease of bone.
The analgesic activity of oral salmon calcitonin has been shown in several controlled prospective double-blind studies; besides pain management in osteoporosis, calcitonin has shown analgesic action in painful conditions such as phantom limb pain, diabetic neuropathy, complex regional pain syndrome, adhesive capsulitis, rheumatoid arthritis, vertebral crush fractures, spondylitis, tumor metastasis, cancer pain, migraine, Paget's disease of bone as well as post-operative pain.
17 Drivers and Barriers for Paget's Disease of Bone Therapeutics Market 33